CN103223057A - Medicine used for enhancing insulin sensitivity - Google Patents

Abstract

The invention discloses a medicine used for enhancing insulin sensitivity. The medicine used for enhancing insulin sensitivity is characterized by comprising the following components in in percentage by weight based on the total weight: 17.3-25.6% of hairyvein agrimony, 23.5-26.5% of cortex lycii radicis, 21.2-24.3% of barbary wolfberry fruit, 18.2-23.3% of milkvetch and 19.8-25.3% of ginseng. The preparation method of the medicine adopts a common preparation method. The components are smashed and mixed to prepare powder or any other pharmaceutical dosage forms. Experiments show that the medicine for enhancing insulin sensitivity can effectively increase content of a glucose transporter 4, and blood glucose level of a diabetes rat can be effectively reduced.

Description

A kind of medicine that increases insulin sensitivity

Technical field

The present invention relates to a kind of medicine that increases insulin sensitivity

Background technology

Diabetes (diabetes) are that multiple virulence factor acts on that body causes hypoinsulinism, insulin resistant etc. and a series of metabolism disorder syndromes such as the sugar that causes, protein, fat, power and water Xie Zhi, are main feature clinically with the hyperglycemia.The overall prevalence of the present diabetes of China has reached 9.7%.The same period prediabetes prevalence up to 15.5%.The reckoning of making according to survey result shows that China total glycosuria sufferer patient number reaches more than 9,000 2 hundred ten thousand, and the prediabetes number reaches more than 100,000,000 4 thousand 8 hundred ten thousand.(glucose transporter4 is the main after birth transport protein of insulin sensitivity target tissue GLUT4) to glucose transporter 4, and the change of its expression and function may relate to muscle and adipose cell insulin resistant.Big quantity research has proved that the main pathology physiological feature of type 2 diabetes mellitus is insulin resistant (insulin resistance, IR), one of its main pathological change is meant the impaired glucose transporter GLUT4 transposition obstacle that causes of insulin signaling pathway in adipose cell and the Skeletal Muscle Cell.Therefore the research of GLUT4 is become a focus of present onset diabetes Mechanism Study.The at present known adjusting that GLUT4 is expressed is not only at transcriptional level, and is present in post-transcriptional level.The concrete molecular mechanism of regulating GLUT4 gene expression in vivo is not clear, and mainly containing physiology, pathological change and medicine all can influence its expression.Physiology and pathologic factor are discovered the adjusting of GLUT4, high fat diet can be reduced the GLUT4 level of rat white adipose tissue, and obviously suppress to be subjected to the insulin regulation and control adipose cell GLUT4 transposition and to the picked-up of glucose, and training can improve under the insulin resistant state content of GLUT4 in the adipose cell and skeletal muscle, promote transhipment and the utilization of adipose cell and muscular tissue, thereby improve impaired glucose tolerance and insulin resistant glucose.There is the report pathologic to destroy GLUT4 gene in the mouse muscle, serious glucose transport obstacle appears in these mices, and just cause severe insulin resistance and glucose tolerance to be gone down in early days, and the expression of endogenous increase GLUT4 can improve db/db Mus diabetes blood glucose situation.The proteic mice of overexpression GLUT4 will significantly increase glucose uptake and utilization on the feed the time.In addition, there are a lot of medicines that the GLUT4 expression of gene is had regulating and controlling effect, study many have insulin, euglycemic agent thiazolidinediones medicine and TNF α etc. at present.Discover that the inductive diabetes of streptozotocin and long-term fasting etc. cause under the state of the relative shortage of insulin, the expression of GLUT4mRNA is significantly reduced.GLUT4 promotes glucose transport and utilization by being indexed into cell membrane in the cell under the insulin stimulating.Under base state, blood insulin is in low-level, and most GLUT4 are positioned at endochylema, and glucose transport absorbed and reduced this moment; After having meal, blood sugar increasing, the B cell uelralante increases, the Insulin receptor INSR of insulin action on adipose cell and myocyte, signal transduction by courier behind the receptor and membrane channels transport protein, GLUT4 is redistributed in cell surface, promote the cell absorption and utilize glucose, thus the blood sugar lowering level.The Sugar intake increase that insulin causes mainly is by stimulating two different signal transduction pathways to carry out, article one, be to act on phosphatidylinositols 3 kinases (PI3K) to cause the GLUT4 transposition, another is by promoting P38MAPK (p38mitogen-activated protein kinase) thereby phosphorylation activates GLUT4 activity [2].Insulin is reversible to the influence of GLUT4 transposition process, and after insulin and receptors bind were dissociated, GLUT4 got back in the vesicle specific in the cell.Insulin redistributes GLUT4 by regulating the speed of GLUT4 transposition in cell, thereby changes glucose transport speed.After research is also found to answer insulinize, the GLUT4 low expression level is recovered in diabetes rat and the diabetics peripheral tissues, and insulin promotes GLUT4 transposition and its activity of raising in the cell, but the insulin of long-time or high concentration can suppress the expression of GLUT4.

Troglitazone (Troglitazone) can improve the inhibitory action of TNF α to adipose cell INS signal path, removes the downward modulation effect of TNF α to GLUT4, and can make the glucose utilization rate of peripheral tissues recover normal.Troglitazone promotes the transposition of GLUT4 in L6 myocyte, but troglitazone is also indeterminate to the direct effect of glucose transporter.Have vitro study to show: rosiglitazone (Rosiglitazone) can increase the Mus myocardial cell to the transhipment of glucose and the expression of GLUT4.Pioglitazone (Pioglitazone) can suppress TNF-α and IL-6 level in fatty tissue and the skeletal muscle, and promotes the expression of GLUT4, improves body peripheral tissues to insulin sensitivity.Big quantity research report is also arranged in addition, and glimepiride has direct insulin mimetic and insulin-sensitizing effect in the adipose cell of isolated culture and muscle.But special protein phosphorylation enzyme in the glimepiride active cell and promote the transposition of glucose transporter 4 (GLUT4) to activate glycogen synthetase reduces glycogen synthase kinase 3 activity, thereby promotes the glucose utilization of peripheral tissues.Tumor necrosis factor (tumor necrosis factor, TNF α) plays an important role in relevant insulin resistant of obesity and diabetes, and closely related with serum insulin levels, glucose metabolism and lipid metabolism.

In the type 2 diabetes mellitus pathogenesis, insulin resistant is an important step, and main diseases one is that the insulin signaling pathway obstacle causes glucose transporter GLUT4 transposition obstacle in adipose cell and the Skeletal Muscle Cell therefore.Therefore GLUT4 becomes an important candidate gene of type 2 diabetes mellitus morbidity.Existing both at home and abroad two kinds of sudden change modes discovering this gene: the missense mutation of GTC--ATC (Val-Ile383) in the nonsense mutation of AAC-AAT (Asn130) and the exon 9 in the exon 4a.Especially relevant with the insulin resistant abnormal carbohydrate metabolism of many discovering, Developmental and Metabolic Disorder can influence the GLUT4 expression of gene.In the low serum insulin diabetes rat of the hyperglycemia due to streptozotocin (STZ) injection, GLUT4mRNA and protein content significantly descend in its adipose cell, and the normal control rats of glucose transport reduces 60% under insulin action.The minimizing that GLUT4 content in the adipose cell is described may be because due to the GLUT4 genetic transcription obstacle.Transgenic animal model studies have shown that GLUT4 is the main effects molecule of insulin-mediated glucose uptake.Overexpression GLUT4 gene, the utilization that especially improves insulin sensitivity and promotion periphery glucose the mice of skeletal muscle and fatty tissue overexpression.High-caliber glucose transporter can improve the insulin sensitivity of hereditary diabetes and diabetes animal model.Therefore, the increase of GLUT4 expression of gene is a kind of molecular mechanism of clinical treatment insulin resistant state.

In sum, adipose cell GLUT4 content reduces, and the especially decline of epicyte GLUT4 expression can directly influence picked-up and the utilization of cell to glucose, and can induce liver, muscle and fatty tissue insulin resistant, thereby reduce the sensitivity of body to insulin.The method of multiple diabetogenic factor and treatment diabetes is to work by the GLUT4 that influence is organized.Therefore, significant about the research between GLUT4 and insulin resistant and the diabetes for treatment and prevent diabetes, also will provide updating strategy simultaneously for the control of diabetes.The traditional Chinese medical science thinks, employing be the comprehensive treatments such as feelings will, appropriate exercise, medicine conditioning of keeping on a diet, take good care of oneself.But, perhaps, make the part patient too high to the expected value of TCM treatment of diabetes owing to the misleading of some unreal advertisement because people not too separate the situation of TCM treatment of diabetes, so that abandon regular treatment, remove to seek the refreshing medicine in celestial being side, influenced the control of the state of an illness, even threat to life.Herba Agrimoniae: nature and flavor hardship, puckery, tepor.Effectiveness: convergence, hemostasis, blood sugar lowering, cough-relieving etc.Cortex Lycii: nature and flavor are sweet, light, cold.Effectiveness: heat clearing away, removing heat from blood, removing fire from the liver.Fructus Lycii: nature and flavor are sweet, flat.Effectiveness: nourishing the liver and kidney.

The medicine that this patent is applied for is with pure natural plant Herba Agrimoniae, Cortex Lycii, Fructus Lycii, the Radix Astragali, the Radix Ginseng hybrid process is refined a kind of medicine that increases insulin sensitivity that forms, and the diabetes that caused by GLUT4 unusual (insulin resistant) are had special curative effect, can raise the expression of GLUT4.Wherein, described Herba Agrimoniae accounts for the percentage ratio of gross weight of described medicine at 17.3%-25.6%; Described Cortex Lycii accounts for the percentage ratio of gross weight of described medicine between 23.5%-26.5%, described Fructus Lycii accounts for the percentage ratio of gross weight of described medicine between 21.2%-24.3%, the described Radix Astragali accounts for the percentage ratio of gross weight of described medicine between 18.2%-23.3%, and described Radix Ginseng accounts for the percentage ratio of gross weight of described medicine between 19.8%-25.3%.

Summary of the invention

1 technical problem to be solved by this invention is to provide a kind of medicine that increases insulin sensitivity, contains 5 flavor Chinese medicines.

2 technical problems to be solved by this invention also are: a kind of medicine that increases insulin sensitivity is provided.

3 these medicines can effectively be treated diabetes and be without any side effects.

Description of drawings

What accompanying drawing 1 had shown that this patent applies for has the medicine of rise effect to have to reduce the effect of diabetes rat adipose cell glucose transporter 4 content to glucose transporter 4, a is a normal group among the figure, the b group, the c group, the d group, the e group, the f group, the g group is diabetes blank group and different medication groups with the h group.

A. normal blank

B. diabetes blank

C. diabetes have the medicine of rise effect with what this patent was applied for to glucose transporter 4

D. diabetes are singly used Herba Agrimoniae

E. diabetes are singly used Cortex Lycii

F. diabetes are singly used Fructus Lycii

G. diabetes are singly used the Radix Astragali

H. diabetes are singly used Radix Ginseng

What accompanying drawing 2 had shown that this patent applies for has the medicine of rise effect that the effect of reduction to blood glucose in diabetic rats arranged to glucose transporter 4, and a is a normal group among the figure, the b group, the c group, d group, e group, the f group, the g group is diabetes blank group and different medication groups with the h group.

I. normal blank

J. diabetes blank

K. diabetes have the medicine of rise effect with what this patent was applied for to glucose transporter 4

L. diabetes are singly used Herba Agrimoniae

M. diabetes are singly used Cortex Lycii

N. diabetes are singly used Fructus Lycii

O. diabetes are singly used the Radix Astragali

P. diabetes are singly used Radix Ginseng.

Claims (1)

1. medicine that increases insulin sensitivity is characterized in that: described this medicine is by Herba Agrimoniae, Cortex Lycii, and Fructus Lycii, the Radix Astragali, Radix Ginseng is formed, and wherein, described Herba Agrimoniae accounts for the percentage ratio of gross weight of described medicine at 17.3%-25.6%; Described Cortex Lycii accounts for the percentage ratio of gross weight of described medicine between 23.5%-26.5%, described Fructus Lycii accounts for the percentage ratio of gross weight of described medicine between 21.2%-24.3%, the described Radix Astragali accounts for the percentage ratio of gross weight of described medicine between 18.2%-23.3%, and described Radix Ginseng accounts for the percentage ratio of gross weight of described medicine between 19.8%-25.3%.

Images